NCT04923048 - A Safety, Tolerability, Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL. | Biotech Hunter

Enrollment

460

Participants

Timeline

Start Date

August 31, 2021

Primary Completion Date

June 28, 2024

Study Completion Date

June 28, 2025

Conditions

B Cell NHLCLL

Interventions

BIOLOGICAL

GB261

Drug:GB261 IV, participants with B-cell NHL or CLL will receive GB261 via IV infusion weekly for the first two cycles(1cycle=21days), followed by Q3W from C3 and afterwards in given doses until progression disease or other situations specified in the protocol, whichever comes earlier.

Trial Locations (6)

2010

RECRUITING

St Vincent's Hospital/The Kinghorn Cancer Centre, Sydney

3004

RECRUITING

Alfred hospital, Melbourne

3144

RECRUITING

Cabrini hospital, Melbourne

3199

TERMINATED

Peninsula & South Eastern Haematology & Oncology Group, Melbourne

5000

RECRUITING

Royal Adelaide Hospital, Adelaide

6153

RECRUITING

One Clinical Research Pty Ltd, Mount Pleasant